| 1 |
NCT01295944 |
Recruiting |
Carboplatin and Bevacizumab for Recurrent Ependymoma |
- Ependymoma
- Anaplastic Ependymoma
|
- Drug: Carboplatin
- Drug: Bevacizumab
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- progression-free survival (PFS) at one year
- To evaluate response rates to this chemotherapy.
- To evaluate overall survival in this population.
- (and 2 more...)
|
35 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT01295944 |
160009
16-C-0009 |
|
October 21, 2015 |
July 1, 2018 |
July 1, 2020 |
February 15, 2011 |
November 24, 2017 |
|
- Harvard Cancer Center
Boston, Massachusetts, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States - MD Anderson Cancer Center
Houston, Texas, United States
|
| 2 |
NCT02722512 |
Recruiting |
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine |
- Glioblastoma Multiforme
- Astrocytoma, Grade III
- Anaplastic Ependymoma
- (and 2 more...)
|
- Biological: Heat Shock Protein Peptide Complex-96 (HSPPC-96)
- Procedure: Tumor Resection
- Radiation: Radiation
|
Interventional |
Phase 1 |
- Ann & Robert H Lurie Children's Hospital of Chicago
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The rolling 6 statistical design will be utilized to establish the MTD and RP2D of HSPCC autologous vaccine in children with newly diagnosed high grade glioma (HGG) following focal radiation therapy and in recurrent HGG and ependymoma given alone.
- To estimate the progression-free survival distribution in children with recurrent and resectable HGG treated with HSPPC-96 vaccine therapy alone (Arm B).
- To estimate the progression-free survival distribution in children with recurrent and resectable ependymoma treated with HSPPC-96 vaccine therapy alone (Arm B).
- To evaluate patient immune responses as measured by immune correlates in the above patient groups.
|
20 |
All |
3 Years to 21 Years (Child, Adult) |
NCT02722512 |
2016-362 |
|
July 2016 |
May 2018 |
May 2019 |
March 30, 2016 |
July 21, 2017 |
|
- Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
|
| 3 |
NCT01478321 |
Active, not recruiting |
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas |
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- (and 2 more...)
|
- Drug: Temozolomide
- Radiation: hypofractionated radiation therapy
- Biological: bevacizumab
- Other: questionnaire administration
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- OS
- Change in neurological status
- Safety profile
- PFS
|
63 |
All |
18 Years and older (Adult, Senior) |
NCT01478321 |
NU 11C02
STU00053636
NCI CTRP# |
|
November 2011 |
November 2019 |
November 2020 |
November 23, 2011 |
April 12, 2018 |
|
- Northwestern University
Chicago, Illinois, United States - University of Chicago
Chicago, Illinois, United States - Northwestern Lake Forest Hospital
Lake Forest, Illinois, United States - (and 2 more...)
|
| 4 |
NCT00243490 |
Withdrawn |
Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors |
- Malignant Intracranial Tumors
- Glioblastoma Multiforme
- Anaplastic Astrocytomas
- (and 2 more...)
|
- Procedure: Photodynamic therapy using Photosan and LumaCare™ Lamp Model LC-122M
|
Interventional |
Phase 2 |
- National Taiwan University Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The addition of photodynamic therapy to standard brain tumor treatments will result in a significant prolongation of time to recurrence and survival in newly diagnosed malignant intracranial tumors.
|
5 |
All |
20 Years to 75 Years (Adult, Senior) |
NCT00243490 |
33MD01 |
|
|
|
January 2009 |
October 24, 2005 |
January 12, 2010 |
|
- National Taiwan University Hospital
Taipei, Taiwan
|
| 5 |
NCT02155920 |
Recruiting |
Everolimus for Children With Recurrent or Progressive Ependymoma |
- Recurrent Childhood Ependymoma
|
|
Interventional |
Phase 2 |
- University of Texas Southwestern Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (Complete Response Rate and Partial Response Rate) following treatment with everolimus for children with recurrent or progressive ependymomas.
- Duration of response following treatment with everolimus for children with recurrent or progressive ependymomas.
- Progression free survival (PRS) following treatment with everolimus for children with recurrent or progressive ependymomas.
- (and 3 more...)
|
18 |
All |
2 Years to 21 Years (Child, Adult) |
NCT02155920 |
CRAD001CUS224T |
|
February 2015 |
February 2018 |
December 2019 |
June 4, 2014 |
December 5, 2016 |
|
- Lucile Packard Children's Hospital Stanford University
Stanford, California, United States - New York University Stephen D. Hassenfeld Children's Center for Cancer & Blood Disorders
New York, New York, United States - UT Southwestern Medical Center / Children's Medical Center
Dallas, Texas, United States - Baylor College of Medicine / Texas Children's Hospital
Houston, Texas, United States
|
| 6 |
NCT01082926 |
Completed |
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 |
- Anaplastic Astrocytoma
- Anaplastic Ependymoma
- Anaplastic Meningioma
- (and 11 more...)
|
- Biological: therapeutic allogeneic lymphocytes
- Biological: aldesleukin
- Other: laboratory biomarker analysis
- Procedure: positron emission tomography
|
Interventional |
Phase 1 |
- City of Hope Medical Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of GRm13Z40-2 CTL CNS loco-regional cellular immunotherapy
- Safety of convection enhanced delivery (CED) of recombinant human Interleukin-2 (rhuIL-2) used in conjunction with GRm13Z40-2 CTL adoptive transfer
- Toxicity as assessed by NCI CTCAE version 4.0
- (and 3 more...)
|
6 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01082926 |
07082
NCI-2010-00303 |
|
May 2010 |
September 2013 |
September 2013 |
March 9, 2010 |
June 8, 2015 |
|
- City of Hope
Duarte, California, United States
|
| 7 |
NCT01095094 |
Terminated
Has Results |
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma |
- Brain Tumor
- Anaplastic Astrocytoma
- Anaplastic Ependymoma
- (and 6 more...)
|
- Drug: ritonavir
- Drug: lopinavir
|
Interventional |
Phase 2 |
- Case Comprehensive Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free Survival
- Grade 3-5 Toxicity as Assessed by NCI CTC v3.0
|
19 |
All |
18 Years and older (Adult, Senior) |
NCT01095094 |
CASE2307
NCI-2009-01288 |
|
January 2009 |
June 2010 |
November 2011 |
March 29, 2010 |
June 10, 2013 |
June 10, 2013 |
- Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
| 8 |
NCT00003479 |
Terminated
Has Results |
Antineoplaston Therapy in Treating Patients With Ependymoma |
|
- Drug: Antineoplaston therapy (Atengenal + Astugenal)
|
Interventional |
Phase 2 |
- Burzynski Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Objective Response
- Percentage of Participants Who Survived
|
9 |
All |
6 Months to 99 Years (Child, Adult, Senior) |
NCT00003479 |
CDR0000066516
BC-BT-24 |
|
July 1966 |
October 2000 |
October 2000 |
January 27, 2003 |
August 24, 2017 |
February 17, 2017 |
- Burzynski Clinic
Houston, Texas, United States
|
| 9 |
NCT01721577 |
Unknown † |
Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas |
- Glioblastoma
- Gliosarcoma
- Anaplastic Astrocytoma
- (and 3 more...)
|
|
Interventional |
Phase 1
Phase 2 |
- Rush University Medical Center
- Axelar AB
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I - Determine recommended Phase II dose.
- Phase II - Determine Antitumor effect
- Phase I - Maximum Tolerated Dose (MTD)
- (and 5 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT01721577 |
11090804
VABC; GCR |
AXL1717 |
December 2012 |
December 2015 |
December 2015 |
November 5, 2012 |
January 12, 2015 |
|
- Rush University Medical Center
Chicago, Illinois, United States
|
| 10 |
NCT03434262 |
Recruiting |
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors |
- Anaplastic Astrocytoma
- Anaplastic Ependymoma
- Anaplastic Ganglioglioma
- (and 53 more...)
|
- Drug: Gemcitabine
- Drug: ribociclib
- Drug: sonidegib
- (and 3 more...)
|
Interventional |
Phase 1 |
- St. Jude Children's Research Hospital
- Novartis Pharmaceuticals
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Estimate the Maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) of each doublet by stratum
- Pharmacokinetics of combination treatment: Stratum A
- Pharmacokinetics of combination treatment: Stratum B
- (and 3 more...)
|
108 |
All |
1 Year to 39 Years (Child, Adult) |
NCT03434262 |
SJDAWN
NCI-2018-00284 |
|
March 5, 2018 |
February 2025 |
March 2025 |
February 15, 2018 |
April 10, 2018 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
| 11 |
NCT02101905 |
Recruiting |
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma |
- Anaplastic Astrocytoma
- Anaplastic Ependymoma
- Anaplastic Oligodendroglioma
- (and 4 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Lapatinib Ditosylate
- Other: Pharmacological Study
- Procedure: Therapeutic Conventional Surgery
|
Interventional |
Not Applicable |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Lapatinib ditosylate intratumoral concentration (pharmacokinetics)
- Ratio of phosphorylated (p)EGFR/total EGFR (PD) in tumor tissue
- Incidence of adverse events (AEs)
- (and 5 more...)
|
33 |
All |
18 Years and older (Adult, Senior) |
NCT02101905 |
NCI-2014-00634
ABTC-1302
U01CA137443
UM1CA137443 |
|
March 13, 2014 |
June 30, 2018 |
|
April 2, 2014 |
April 13, 2018 |
|
- UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - (and 9 more...)
|
| 12 |
NCT01836549 |
Completed |
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors |
- Anaplastic Astrocytoma
- Anaplastic Ependymoma
- Astrocytoma, Grade II
- (and 6 more...)
|
|
Interventional |
Phase 2 |
- Pediatric Brain Tumor Consortium
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Molecular biology study: Percentage of subjects with telomerase-positive archival tumors who demonstrate at least 50% reduction in telomerase activity
- Phase II: Stratum-specific objective response (CR+PR) rate
- Quantitative assessments of hTERT mRNA and TERC RNA levels (Molecular biology study)
- (and 4 more...)
|
43 |
All |
12 Months to 21 Years (Child, Adult) |
NCT01836549 |
PBTC-036
NCI-2013-00482
U01CA081457 |
|
March 2013 |
April 2016 |
April 2016 |
April 22, 2013 |
April 12, 2016 |
|
- Childrens Hospital Los Angeles
Los Angeles, California, United States - Lucile Packard Children's Hospital at Stanford University Medical Center
Palo Alto, California, United States - Children's National Medical Center
Washington, District of Columbia, United States - (and 8 more...)
|
| 13 |
NCT02175745 |
Terminated
Has Results |
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas |
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- Adult Brain Stem Glioma
- (and 54 more...)
|
- Drug: 18F-fluoro-dihydroxyphenylalanine
- Procedure: Positron emission tomography (PET)
- Procedure: Computed tomography (CT)
- Procedure: Magnetic resonance imaging
|
Interventional |
Not Applicable |
- Erik Mittra
- National Cancer Institute (NCI)
- Stanford University
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Number of Suspicious Lesions Identified by 18F FDOPA PET
- Percent Agreement of 18F FDOPA PET With Pathology
|
2 |
All |
16 Years and older (Child, Adult, Senior) |
NCT02175745 |
IRB-29364
NCI-2014-01289
BRN0024
P30CA124435 |
|
December 2014 |
August 2015 |
December 2015 |
June 26, 2014 |
March 20, 2017 |
March 20, 2017 |
- Stanford University Hospitals and Clinics
Stanford, California, United States
|
| 14 |
NCT02186509 |
Active, not recruiting |
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas |
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- (and 11 more...)
|
- Radiation: Hyperfractionated radiation therapy
- Radiation: Stereotactic radiosurgery
- Drug: Alisertib
- Procedure: Quality-of-life assessment
|
Interventional |
Phase 1 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Millennium Pharmaceuticals, Inc.
- Thomas Jefferson University
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of alisertib
- Proportion of patients at the MTD with complete or partial response
- Progression free survival among patients at the MTD based on brain magnetic resonance imaging and defined according to updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Work Group
- Overall survival among patients at the MTD
|
17 |
All |
18 Years and older (Adult, Senior) |
NCT02186509 |
13P.528
2013-12 |
|
January 30, 2015 |
March 31, 2017 |
January 2019 |
July 10, 2014 |
October 27, 2017 |
|
- Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
| 15 |
NCT01996527 |
Terminated |
3T MRI Biomarkers of Glioma Treatment Response |
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- (and 4 more...)
|
- Device: 3-Tesla magnetic resonance imaging
- Device: CEST-MRI
- Device: DW-MRI
- (and 3 more...)
|
Interventional |
Early Phase 1 |
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Best Response
- Progression Free Survival (PFS)
|
7 |
All |
18 Years and older (Adult, Senior) |
NCT01996527 |
VICC NEU 1268
NCI-2013-02195
P30CA068485 |
|
May 2012 |
November 23, 2015 |
January 1, 2016 |
November 27, 2013 |
April 17, 2017 |
|
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
|
| 16 |
NCT02967380 |
Terminated |
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases |
- Adult Anaplastic (Malignant) Meningioma
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- (and 22 more...)
|
- Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Drug: Gadobenate Dimeglumine
- Drug: Gadobutrol
- Radiation: Gadopentetate Dimeglumine
|
Interventional |
Not Applicable |
- University of Southern California
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Agreement of using Magnevist® or Multihance versus Gadavist® on glioma grading
|
14 |
All |
18 Years and older (Adult, Senior) |
NCT02967380 |
0S-11-6
NCI-2014-01852
D1 2010-10
HS-11-00363
P30CA014089 |
|
December 14, 2011 |
October 14, 2014 |
October 14, 2015 |
November 18, 2016 |
March 27, 2017 |
|
- USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
|
| 17 |
NCT01234805 |
Terminated |
Yoga Therapy in Treating Patients With Malignant Brain Tumors |
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Meningioma
- (and 20 more...)
|
- Procedure: yoga therapy
- Other: questionnaire administration
- Procedure: quality-of-life assessment
|
Interventional |
Not Applicable |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Estimate the participation rate, accrual, adherence, and retention to a yoga trial in patients with malignant brain tumors
- Self-reported fatigue
- Depressive symptoms
- (and 4 more...)
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT01234805 |
CCCWFU 98410
NCI-2010-02044 |
|
December 2010 |
September 2012 |
|
November 4, 2010 |
August 1, 2017 |
|
- Comprehensive Cancer Center of Wake Forest University
Winston-Salem, North Carolina, United States
|
| 18 |
NCT01234740 |
Completed |
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases |
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- (and 7 more...)
|
- Drug: bafetinib
- Procedure: microdialysis
- Other: pharmacological study
- (and 7 more...)
|
Interventional |
Phase 1 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Area-under-the-concentration-time-curve (AUC) of bafetinib in dialysate
- Peak concentration (Cmax) of bafetinib in dialysate
- AUC of bafetinib in plasma
- (and 6 more...)
|
7 |
All |
18 Years and older (Adult, Senior) |
NCT01234740 |
10134
NCI-2010-01963 |
|
December 2010 |
March 2013 |
March 2013 |
November 4, 2010 |
April 17, 2018 |
|
- City of Hope Medical Center
Duarte, California, United States - South Pasadena Cancer Center
South Pasadena, California, United States
|
| 19 |
NCT01165632 |
Active, not recruiting |
Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma |
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- (and 13 more...)
|
- Procedure: biopsy
- Procedure: computed tomography
- Procedure: therapeutic conventional surgery
- (and 5 more...)
|
Interventional |
Not Applicable |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- 18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies
- 18F- FDOPA-PET metabolic imaging information
- Concordance of 18F-FDOPA PET and 11C-choline activity, MRI contrast enhancement, and high- or low-grade glioma biopsies
- (and 2 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT01165632 |
MC1078
NCI-2010-01607
10-001904 |
|
July 2010 |
July 2018 |
July 2018 |
July 20, 2010 |
November 17, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
| 20 |
NCT01131234 |
Completed |
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors |
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- (and 49 more...)
|
- Drug: Gamma-Secretase Inhibitor RO4929097
- Drug: Cediranib Maleate
- Other: Pharmacological Study
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recommended phase II dose of gamma-secretase inhibitor RO4929097 defined as the dose level at which < 1/6 patients experience dose-limiting toxicity as graded by the National Cancer Institute (NCI) CTCAE version 4.0
- Incidence of adverse events as graded by the NCI CTCAE version 4.0
- PK profiles for both drugs
- (and 2 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT01131234 |
NCI-2011-01428
CDR0000673867
PJC-004
8503
U01CA132123 |
|
May 2010 |
September 2014 |
September 2014 |
May 26, 2010 |
December 23, 2014 |
|
- Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada - University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
|
| 21 |
NCT02194452 |
Withdrawn |
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors |
- Acoustic Schwannoma
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- (and 92 more...)
|
- Radiation: gallium Ga 68-edotreotide
- Procedure: positron emission tomography
- Procedure: computed tomography
- Other: laboratory biomarker analysis
|
Interventional |
Not Applicable |
- Sue O'Dorisio
- National Cancer Institute (NCI)
- Ride for Kids
- University of Iowa
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Change in standardized uptake value (SUV) uptake after gallium Ga 68-edotreotide
- Proportion of discordance and concordance between gallium Ga 68-edotreotide and biopsy
|
0 |
All |
6 Months to 29 Years (Child, Adult) |
NCT02194452 |
201302711
P30CA086862 |
|
September 2013 |
March 2017 |
March 2017 |
July 18, 2014 |
April 28, 2017 |
|
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
|
| 22 |
NCT00492089 |
Completed
Has Results |
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer |
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Meningioma
- (and 84 more...)
|
- Drug: bevacizumab
- Drug: placebo
- Procedure: magnetic resonance imaging
- Procedure: quality-of-life assessment
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Supportive Care
|
- Number of Participants With Response ( > 25% Reduction in T2 Flair) From Baseline to Evaluation at 6 Weeks Post Treatment
|
11 |
All |
18 Years and older (Adult, Senior) |
NCT00492089 |
NCI-2009-00256
CDR0000553135
2006-0890
7955
P30CA016672
N01CM62202 |
|
June 2007 |
August 2010 |
August 2010 |
June 27, 2007 |
May 9, 2014 |
June 14, 2013 |
- M D Anderson Cancer Center
Houston, Texas, United States
|
| 23 |
NCT00430079 |
Terminated |
Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma |
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- (and 11 more...)
|
- Drug: etanidazole
- Procedure: conventional surgery
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional |
Not Applicable |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Time to local recurrence
- Time to death
- Presence and pattern of EF5 binding in newly diagnosed brain masses by IHC analyses
- (and 3 more...)
|
48 |
All |
18 Years and older (Adult, Senior) |
NCT00430079 |
NCI-2012-02419
UPCC# 1301
R21CA093007
CDR0000068962 |
|
July 2001 |
September 2007 |
|
February 1, 2007 |
January 16, 2013 |
|
- Abramson Cancer Center of The University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 24 |
NCT00110032 |
Terminated |
Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors |
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- (and 24 more...)
|
- Drug: EF5
- Procedure: conventional surgery
- Procedure: positron emission tomography
- (and 2 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Safety of F-18-EF5 based on the NCI CTCAE version 3.0
- Pharmacokinetics of radioactively labeled [F-18]-EF5
- Extent of hypoxia, determined by [F-18]-EF5 PET imaging
- (and 2 more...)
|
46 |
All |
18 Years and older (Adult, Senior) |
NCT00110032 |
NCI-2012-02651
UPCC 01304
CDR0000423313 |
|
June 2005 |
January 2007 |
|
May 4, 2005 |
January 16, 2013 |
|
- Abramson Cancer Center of The University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 25 |
NCT00030498 |
Completed |
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction |
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- (and 83 more...)
|
- Drug: erlotinib hydrochloride
- Other: laboratory biomarker analysis
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of OSI-774 determined by dose-limiting toxicities
|
75 |
All |
18 Years and older (Adult, Senior) |
NCT00030498 |
NCI-2012-01868
CALGB-60101
U10CA031946
CDR0000069170 |
|
December 2001 |
July 2007 |
|
January 27, 2003 |
January 16, 2013 |
|
- Cancer and Leukemia Group B
Chicago, Illinois, United States
|
| 26 |
NCT01119599 |
Completed |
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma |
- Acoustic Schwannoma
- Adult Anaplastic (Malignant) Meningioma
- Adult Anaplastic Astrocytoma
- (and 26 more...)
|
- Radiation: 3-Dimensional Conformal Radiation Therapy
- Drug: Gamma-Secretase Inhibitor RO4929097
- Radiation: Intensity-Modulated Radiation Therapy
- (and 4 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose defined as the highest dose studied for which the incidence of dose limiting toxicity is less than 33% using National Cancer Institute Common Toxicity Criteria
- Changes in MRI parameters
- Percent changes in serum YKL-40 levels and hair follicle HES1 levels
- Pharmacokinetic (PK) parameters of gamma-secretase/Notch signalling pathway inhibitor RO4929097
|
22 |
All |
19 Years and older (Adult, Senior) |
NCT01119599 |
NCI-2011-01410
CDR0000672641
09-177
8556
P30CA008748
U01CA069856 |
|
May 2010 |
June 2013 |
|
May 7, 2010 |
September 29, 2015 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States - University of Virginia Cancer Center
Charlottesville, Virginia, United States
|
| 27 |
NCT00002876 |
Completed |
Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas |
- Brain and Central Nervous System Tumors
|
- Drug: cisplatin
- Drug: etoposide
|
Interventional |
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
35 |
All |
18 Years and older (Adult, Senior) |
NCT00002876 |
CDR0000065162
P30CA015083
907253
V96-1072
394-91 |
|
October 1991 |
April 1998 |
January 2005 |
May 21, 2004 |
May 11, 2011 |
|
- Mayo Clinic Scottsdale
Scottsdale, Arizona, United States - Mayo Clinic Jacksonville
Jacksonville, Florida, United States - Mayo Clinic Cancer Center
Rochester, Minnesota, United States
|
| 28 |
NCT00003309 |
Completed |
Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer |
- Brain and Central Nervous System Tumors
|
- Biological: filgrastim
- Drug: cisplatin
- Drug: cyclophosphamide
- (and 4 more...)
|
Interventional |
Phase 2 |
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Primary Purpose: Treatment
|
|
33 |
All |
18 Years and older (Adult, Senior) |
NCT00003309 |
CDR0000066256
E4397
SWOG-E4397 |
|
July 1998 |
March 2004 |
|
January 27, 2003 |
January 27, 2010 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States - Veterans Affairs Medical Center - Lakeside Chicago
Chicago, Illinois, United States - Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, United States - (and 11 more...)
|
| 29 |
NCT00058123 |
Completed |
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma |
- Brain and Central Nervous System Tumors
|
|
Interventional |
Phase 2 |
- Sidney Kimmel Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression within 6 months
|
46 |
All |
18 Years and older (Adult, Senior) |
NCT00058123 |
ABTC-0106 CDR0000287012
U01CA062399
ABTC-0106 |
|
March 2003 |
September 2009 |
November 2009 |
April 9, 2003 |
August 12, 2014 |
|
- Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States - UCSF Comprehensive Cancer Center
San Francisco, California, United States - Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, United States - (and 5 more...)
|
| 30 |
NCT00826241 |
Unknown † |
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma |
- Brain Tumors
- Spinal Cord Tumors
|
- Drug: Temozolomide
- Drug: Lapatinib
|
Interventional |
Phase 2 |
- National Institutes of Health Clinical Center (CC)
- CERN Foundation - Collaborative Ependymoma Research Network
|
NIH / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to Progression
- Anti-Tumor Activity
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT00826241 |
999916005
NCI-2012-02131
16-C-N005 |
|
January 2009 |
January 2017 |
|
January 22, 2009 |
October 22, 2015 |
|
- University of California, San Francisco
San Francisco, California, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States - (and 3 more...)
|
| 31 |
NCT00876499 |
Completed |
Fatigue, Sleep and Cytokines in Primary Brain Tumor (PBT) Patients |
|
- Behavioral: Questionnaire
|
Observational |
|
- M.D. Anderson Cancer Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Patient Responses to Brief Fatigue Inventory (BFI)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT00876499 |
2008-0747 |
|
January 2009 |
December 2013 |
December 2013 |
April 6, 2009 |
January 9, 2015 |
|
- UT MD Anderson Cancer Center
Houston, Texas, United States
|
| 32 |
NCT00276770 |
Completed |
Positron Emission Tomography Using Fluorothymidine F 18 in Finding Recurrent Disease in Patients With Gliomas |
- Brain and Central Nervous System Tumors
|
- Other: fluorine F 18 fluorothymidine
- Procedure: positron emission tomography
|
Interventional |
Not Applicable |
- University of Washington
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT00276770 |
CDR0000455011
UW-6230
NCI-7223 |
|
February 2006 |
May 2007 |
|
January 13, 2006 |
December 13, 2012 |
|
- University Cancer Center at University of Washington Medical Center
Seattle, Washington, United States
|
| 33 |
NCT01480050 |
Completed |
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma |
- Brain and Central Nervous System Tumors
|
- Drug: temozolomide
- Other: 3'-deoxy-3'-[18F]fluorothymidine
- Other: pharmacological study
- Drug: Mibefradil
|
Interventional |
Phase 1 |
- Sidney Kimmel Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Cavion, Inc.
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose of mibefradil dihydrochloride
- Dose-limiting toxicity
- Toxicity and adverse events according to CTCAE v. 4.0
- (and 3 more...)
|
28 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT01480050 |
ABTC-1101 CDR0000716313
ABTC-1101 |
|
April 2012 |
August 2015 |
|
November 28, 2011 |
October 14, 2016 |
|
- UAB Comprehensive Cancer Center
Birmingham, Alabama, United States - Winship Cancer Institute of Emory University
Atlanta, Georgia, United States - Johns Hopkins University
Baltimore, Maryland, United States - (and 4 more...)
|
| 34 |
NCT00376818 |
Completed |
Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers |
- Brain and Central Nervous System Tumors
- Psychosocial Effects of Cancer and Its Treatment
|
- Behavioral: exercise intervention
- Other: educational intervention
- Other: physiologic testing
- (and 3 more...)
|
Interventional |
Not Applicable |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Quality of life as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items (EORTC QLQ-C30) and Brain Cancer Module-20
- Decrease in perception of stress and anxiety in patients and their primary family caregivers as measured by the Perceived Stress Scale and Beck Anxiety Inventory questionnaires
- Decrease in stress- and inflammation-related hormones in patients and their primary family caregivers as measured by saliva samples
|
4 |
All |
18 Years and older (Adult, Senior) |
NCT00376818 |
CASE2306
P30CA043703 |
|
June 2006 |
April 2008 |
April 2008 |
September 15, 2006 |
June 4, 2012 |
|
- Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
|
| 35 |
NCT01009307 |
Completed |
Study of Blood and Cheek Cell Samples From Patients With Glioma |
- Brain and Central Nervous System Tumors
|
- Genetic: polymorphism analysis
- Other: laboratory biomarker analysis
- Other: medical chart review
|
Observational |
|
- University of California, San Francisco
- National Cancer Institute (NCI)
|
Other / NIH |
|
- Factors related to glioma survival
|
1709 |
All |
18 Years and older (Adult, Senior) |
NCT01009307 |
CDR0000437072
UCSF-H6539-04956-13A |
|
October 2001 |
July 2006 |
|
November 6, 2009 |
May 15, 2015 |
|
- UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
|
| 36 |
NCT00756106 |
Terminated |
MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma |
- Brain and Central Nervous System Tumors
|
- Drug: temozolomide
- Other: imaging biomarker analysis
|
Observational |
|
- Massachusetts General Hospital
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Relative cerebral blood volume/flow, mean transit time, and mean vessel diameter as measured by perfusion-weighted MRI before, during, and after chemoradiotherapy
- Permeability-surface area product before, during, and after chemoradiotherapy
- Full water self-diffusion tensor before, during, and after chemoradiotherapy
- (and 5 more...)
|
16 |
All |
18 Years and older (Adult, Senior) |
NCT00756106 |
CDR0000600751
MGH-07-292 |
|
July 2008 |
September 2011 |
|
September 19, 2008 |
February 7, 2014 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 37 |
NCT00730613 |
Completed |
Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma |
- Brain and Central Nervous System Tumors
|
- Biological: therapeutic autologous lymphocytes
- Genetic: gene expression analysis
- Other: laboratory biomarker analysis
|
Interventional |
Phase 1 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility
- Safety
- Anti-tumor activity of adoptively transferred clones
- (and 2 more...)
|
3 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00730613 |
01020
P30CA033572
CHNMC-01020
CDR0000590506 |
|
February 2002 |
August 2011 |
August 2011 |
August 8, 2008 |
October 9, 2017 |
|
|
| 38 |
NCT00255671 |
Completed |
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders |
- Brain and Central Nervous System Tumors
- Metastatic Cancer
- Radiation Toxicity
|
|
Observational |
|
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Short-term adverse effects as assessed by a questionnaire
|
76 |
All |
18 Years and older (Adult, Senior) |
NCT00255671 |
CASE4Z05
P30CA043703
CCF-8078 |
|
May 2005 |
April 2008 |
May 2012 |
November 21, 2005 |
October 2, 2015 |
|
- Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
|
| 39 |
NCT01026493 |
Completed
Has Results |
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma |
- Brain and Central Nervous System Tumors
|
- Drug: temozolomide 60 mg x 21 days
- Drug: temozolomide 75 mg x 21 days
- Drug: ABT-888 20 mg x 21 days
- (and 3 more...)
|
Interventional |
Phase 1
Phase 2 |
- Radiation Therapy Oncology Group
- National Cancer Institute (NCI)
- NRG Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1: Maximum Tolerated Dose (MTD)
- Phase II: 6-month Progression-free Survival (PFS) Rate for Patients With Measurable Disease After Surgery
- Phase II: Objective Response (Partial and Complete Response) Rate for Patients With Measurable Disease After Surgery
- Phase II: Overall Survival (OS)
|
257 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT01026493 |
RTOG-0929
CDR0000660545 |
|
July 2010 |
May 2014 |
December 2016 |
December 4, 2009 |
July 2, 2017 |
July 2, 2017 |
- Rebecca and John Moores UCSD Cancer Center
La Jolla, California, United States - Cedars-Sinai Medical Center
Los Angeles, California, United States - Leeward Radiation Oncology
'Ewa Beach, Hawaii, United States - (and 14 more...)
|
| 40 |
NCT01032200 |
Completed
Has Results |
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors |
- Brain Tumors
- Nervous System Tumors
- Cognition Disorders
- Fatigue
|
- Drug: Armodafinil
- Other: placebo
|
Interventional |
Phase 2 |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Retention
- Adherence
- Fatigue
- (and 2 more...)
|
54 |
All |
18 Years and older (Adult, Senior) |
NCT01032200 |
REBACCCWFU97509
U10CA081851 |
|
August 2010 |
November 2013 |
November 2013 |
December 15, 2009 |
November 17, 2017 |
February 13, 2017 |
- Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
|
| 41 |
NCT00967200 |
Completed |
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors |
- Central Nervous System Lymphoma
|
- Other: laboratory biomarker analysis
- Other: pharmacogenomic studies
|
Observational |
|
- University Hospital, Montpellier
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Pathophysiology of gliomas
- Identification of molecular
|
180 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00967200 |
7745 |
|
November 2003 |
July 2009 |
November 2015 |
August 27, 2009 |
November 24, 2015 |
|
- CHU Montpellier
Montpellier, France - Clinique Gui de Chauliac
Montpellier, France
|
| 42 |
NCT00005083 |
Withdrawn |
Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors |
- Brain and Central Nervous System Tumors
|
- Procedure: conventional surgery
- Procedure: magnetic resonance imaging
- Procedure: magnetic resonance spectroscopic imaging
|
Interventional |
Phase 2 |
- Jonsson Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Diagnostic
|
|
0 |
All |
18 Years to 55 Years (Adult) |
NCT00005083 |
CDR0000067692
UCLA-9712069
NCI-G00-1726 |
|
March 1998 |
|
|
December 16, 2003 |
October 4, 2012 |
|
|
| 43 |
NCT00784914 |
Completed |
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors |
- Brain and Central Nervous System Tumors
- Metastatic Cancer
|
- Drug: temsirolimus
- Other: pharmacological study
- Other: cytokine levels
|
Interventional |
Phase 1 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of using a microdialysis catheter to assess the neuropharmacodynamics (nPD) of temsirolimus
- Changes in intracerebral levels of vascular endothelial growth factor (VEGF), interleukin-1ß (IL-1ß), and other cytokines
- Relationship between temsirolimus dose and changes in intracerebral levels of VEGF, IL-1ß, and other cytokines
- (and 3 more...)
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT00784914 |
07064
P30CA033572
CHNMC-07064
CDR0000617019 |
|
June 2008 |
November 2010 |
November 2010 |
November 4, 2008 |
April 17, 2018 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
|
| 44 |
NCT00516607 |
Unknown † |
Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas |
- Brain and Central Nervous System Tumors
|
- Drug: enzastaurin hydrochloride
- Drug: temozolomide
- Other: pharmacological study
|
Interventional |
Phase 1 |
- European Organisation for Research and Treatment of Cancer - EORTC
|
Other |
- Allocation: Non-Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recommended phase II dose
- Dose-limiting toxicity
- Response rate
- (and 3 more...)
|
28 |
All |
18 Years and older (Adult, Senior) |
NCT00516607 |
EORTC-26054 |
|
July 2007 |
November 2008 |
|
August 15, 2007 |
February 10, 2015 |
|
- Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom
|
| 45 |
NCT00009854 |
Unknown † |
Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm |
- Brain and Central Nervous System Tumors
- Metastatic Cancer
|
- Drug: carmustine in ethanol
- Procedure: conventional surgery
|
Interventional |
Phase 1
Phase 2 |
- Direct Therapeutics
- National Cancer Institute (NCI)
|
Industry |
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 75 Years (Adult, Senior) |
NCT00009854 |
CDR0000068416
DTI-0002
UCSF-H7858-17520-01
NCI-V00-1642 |
|
June 2000 |
|
|
January 27, 2003 |
November 6, 2013 |
|
- UCSF Cancer Center and Cancer Research Institute
San Francisco, California, United States - Massey Cancer Center
Richmond, Virginia, United States
|
| 46 |
NCT00004028 |
Completed |
Carmustine in Treating Patients With Recurrent Malignant Glioma |
- Brain and Central Nervous System Tumors
|
- Drug: carmustine
- Procedure: conventional surgery
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00004028 |
CDR0000065129
NABTT-101-9601
JHOC-NABTT-101-9601
NCI-T96-0052H |
|
September 1996 |
|
|
January 27, 2003 |
February 9, 2009 |
|
- University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States - H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States - Emory University Hospital - Atlanta
Atlanta, Georgia, United States - (and 6 more...)
|
| 47 |
NCT00629889 |
Completed |
Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors |
- Brain and Central Nervous System Tumors
- Seizure
|
- Drug: levetiracetam
- Drug: pregabalin
|
Interventional |
Phase 2 |
- Dr Andrea Rossetti
- Centre Hospitalier Universitaire Vaudois
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Survival without occurrence of status epilepticus, 2 seizures with consciousness impairment, need to add a second antiepileptic drug (AED) (except transitory benzodiazepine), and need to discontinue study drug for lack of efficacy or adverse events
- Adverse events
- Anxiety
- (and 4 more...)
|
52 |
All |
18 Years and older (Adult, Senior) |
NCT00629889 |
CDR0000586523
CHUV-Neurology-CePO-LEV-PGB
EU-20807 |
|
February 2008 |
May 2012 |
May 2013 |
March 6, 2008 |
May 22, 2013 |
|
- Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland - USZ
Zürich, Switzerland
|
| 48 |
NCT00544284 |
Completed |
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment |
- Brain and Central Nervous System Tumors
- Lymphoma
- Metastatic Cancer
- Unspecified Adult Solid Tumor, Protocol Specific
|
- Drug: bortezomib
- Drug: temozolomide
- Other: pharmacological study
|
Interventional |
Phase 1 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicity and maximum tolerated dose
- Pharmacokinetics
- Confirmed complete or partial response
- Percentage of patients with 6-month progression-free survival
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT00544284 |
04032
P30CA033572
CHNMC-04032
CDR0000570245 |
|
January 2005 |
January 2012 |
January 2012 |
October 16, 2007 |
February 15, 2013 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - City of Hope Medical Group
Pasadena, California, United States
|
| 49 |
NCT00541138 |
Completed |
Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors |
- Brain and Central Nervous System Tumors
- Metastatic Cancer
- Unspecified Adult Solid Tumor, Protocol Specific
|
- Drug: carboplatin
- Drug: tamoxifen citrate
- Drug: topotecan hydrochloride
- Other: pharmacological study
|
Interventional |
Phase 2 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicity profile as assessed by NCI CTC v2.0
- Response rate in patients with recurrent glial tumors as assessed by RECIST criteria
- Response rate in patients with epithelial CNS metastases as assessed by RECIST criteria
- (and 3 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT00541138 |
02191
P30CA033572
CHNMC-02191
CDR0000570253 |
|
May 2003 |
October 2007 |
October 2007 |
October 8, 2007 |
September 21, 2011 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
|
| 50 |
NCT00538850 |
Completed
Has Results |
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain |
|
- Drug: Fentanyl sublingual spray
- Drug: Placebo
|
Interventional |
Phase 3 |
- INSYS Therapeutics Inc
- National Cancer Institute (NCI)
|
Industry / NIH |
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30)
- Summed Pain Intensity Differences (SPID) at 5, 10, 15, 45, and 60 Minutes After Dosing
- Total Pain Relief (TOTPAR) at 5, 10, 15, 30, 45, and 60 Minutes After Dosing
- Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing
|
130 |
All |
18 Years and older (Adult, Senior) |
NCT00538850 |
INS-05-001
CDR0000581128 |
|
October 2007 |
February 2010 |
October 2010 |
October 3, 2007 |
March 5, 2014 |
March 5, 2014 |
- InSys Therapeutics, Incorporated
Chandler, Arizona, United States
|
Create an RSS feed from your search for:
Download the search results for: